CFO
BMRN icon

CVA Family Office’s BioMarin Pharmaceuticals BMRN Stock Holding History

CVA Family Office’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.79K Buy
171
+2
+1% +$110 ﹤0.01% 1028
2026
Q1 		$9.55K Buy
+169
New +$9.85K ﹤0.01% 1006
2025
Q4 		– Sell
-82
Closed -$4.44K – 1294
2025
Q3 		$4.44K Sell
82
-8
-9% -$458 ﹤0.01% 909
2025
Q2 		$4.95K Sell
90
-14
-13% -$824 ﹤0.01% 891
2025
Q1 		$7.35K Buy
104
+65
+167% +$4.37K ﹤0.01% 843
2024
Q4 		$2.56K Buy
39
+33
+550% +$2.21K ﹤0.01% 953
2024
Q3 		$422 Sell
6
-56
-90% -$4.68K ﹤0.01% 1246
2024
Q2 		$5.1K Buy
62
+12
+24% +$999 ﹤0.01% 828
2024
Q1 		$4.37K Hold
50
– – ﹤0.01% 850
2023
Q4 		$4.82K Buy
+50
New +$4.42K ﹤0.01% 822
2023
Q3 		– Sell
-55
Closed -$4.77K – 320
2023
Q2 		$4.77K Hold
55
– – ﹤0.01% 818
2023
Q1 		$5.35K Sell
55
-5
-8% -$518 ﹤0.01% 768
2022
Q4 		$6.21K Buy
60
+5
+9% +$469 ﹤0.01% 716
2022
Q3 		$5K Hold
55
– – ﹤0.01% 711
2022
Q2 		$5K Sell
55
-5
-8% -$398 ﹤0.01% 737
2022
Q1 		$5K Buy
60
+10
+20% +$837 ﹤0.01% 763
2021
Q4 		$4K Sell
50
-75
-60% -$6.19K ﹤0.01% 766
2021
Q3 		$10K Buy
+125
New +$9.86K 0.01% 294
2021
Q1 		– Sell
-125
Closed -$11K – 777
2020
Q4 		$11K Hold
125
– – 0.01% 293
2020
Q3 		$10K Hold
125
– – 0.01% 294
2020
Q2 		$15K Hold
125
– – 0.01% 235
2020
Q1 		$11K Buy
+125
New +$10.8K 0.01% 233

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

CVA Family Office's BMRN Position: Q2 2026 in Review

CVA Family Office increased its BioMarin Pharmaceuticals (BMRN) stake by 1.2% in Q2 2026, buying an estimated $110 and bringing the position to 171 shares worth $9.79K. The position accounts for ﹤0.01% of the portfolio, ranked #1028.

CVA Family Office first reported a position in BMRN in Q1 2020 and has held it in 22 quarters since. The position peaked at $15K in Q2 2020. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • CVA Family Office held 171 shares of BioMarin Pharmaceuticals worth $9.79K as of Q2 2026.
  • CVA Family Office bought 2 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $110.
  • BioMarin Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1028 holding.
  • CVA Family Office first reported a position in BioMarin Pharmaceuticals in Q1 2020 and has held it in 22 quarters since.
  • CVA Family Office's BioMarin Pharmaceuticals position peaked at $15K in Q2 2020.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.